Metabolic Health 1/2: The Topic That Influences Far More Than Weight

📌 This is Part 1 of our two-part series on metabolic health. In Part 2, we look at the factors that actively degrade metabolic health and the most effective levers to sustainably improve metabolic flexibility.

We often talk about weight. Far less about metabolic health.

And yet, it is probably one of the most determining factors when it comes to energy, body composition, ageing, cardiovascular health, recovery, cognitive function, and hormonal balance.

Because metabolism is not only about weight: it shapes the way the body produces energy, recovers, adapts to physiological stress, and evolves with age.

Metabolic decline is rarely sudden. It develops gradually, often silently, sometimes over years before a diagnosis appears.

That is precisely what makes the subject so important: by the time markers become frankly pathological, the underlying terrain has often been disrupted for a long time.

What we mean by "metabolic health"

ASSET

Infographic: "What is metabolic health?" with its pillars and one-line descriptors: blood sugar regulation (stable glucose & insulin response), blood pressure (healthy cardiovascular regulation), lipid profile (balanced triglycerides & HDL), body composition (preserved muscle mass & low visceral fat), inflammation (controlled low-grade inflammation), and stable energy and appetite.

Metabolic health refers to the body's ability to produce, use, and regulate energy efficiently.

This involves:

• effective glucose management;

• an appropriate insulin response;

• the ability to switch efficiently between different energy sources;

• relatively controlled inflammation;

• good capacity to produce and use energy;

• and sufficient muscle mass to support these mechanisms.

In other words: an organism capable of adapting.

Adapting to a meal, an effort, a period of stress, a variation in energy expenditure. This adaptive capacity, often referred to as metabolic flexibility, is central.

And contrary to what many assume, being slim does not necessarily mean being metabolically healthy. Some people present unstable blood sugar, low muscle mass, high visceral fat, or chronic inflammation despite a "normal" silhouette. Conversely, weight alone can never summarise the true quality of a metabolic terrain.

Two individuals can have the same age, the same weight and a profoundly different physiology.

How is metabolic health measured?

Metabolic health is assessed through several parameters that reflect how the body regulates glucose, lipids, blood pressure, inflammation, and body composition.

In practice, the key markers include:

• fasting blood glucose;

• fasting insulin;

• HbA1c;

• triglycerides;

• HDL cholesterol;

• blood pressure;

• waist circumference;

• certain inflammatory markers;

• and body composition.

The goal is not to interpret a single number in isolation, but to understand the overall coherence of the metabolic terrain. A normal fasting glucose does not necessarily mean the system is functioning optimally. Similarly, a "normal" weight gives no information about visceral fat, muscle mass, or the true quality of the metabolic terrain.

Insulin: a central metabolic hormone

At the heart of this dynamic lies one hormone: insulin.

Produced by the pancreas, it enables glucose to leave the bloodstream and enter cells, particularly muscle cells, to be used as energy or stored.

When an organism is insulin-sensitive, a small amount of insulin is sufficient to manage glucose efficiently after a meal.

But various factors can progressively reduce this sensitivity:

• sedentary lifestyle;

• loss of muscle mass;

• insufficient sleep;

• chronic energy excess;

• stress;

• inflammation;

• gut microbiota disruption;

• ageing.

The pancreas must then produce more insulin to maintain normal blood glucose levels.

And here lies an important nuance: blood glucose "within normal range" does not necessarily mean the metabolism is functioning optimally.

The body is capable of compensating for a long time before glucose levels become frankly abnormal. In other words: a metabolism can already be under strain while blood tests still appear "reassuring."

ASSET

Illustration of insulin resistance: an insulin-sensitive cell takes up glucose easily, while an insulin-resistant cell forces the pancreas to secrete progressively more insulin to keep blood glucose normal.

Insulin resistance does not only concern diabetes. It progressively influences many physiological systems:

• abdominal fat storage;

• cravings;

• energy levels;

• inflammation;

• hormonal disruptions;

• recovery;

• cardiovascular health;

• and hepatic and cognitive health.

Post-meal glucose variations are normal. The body is designed to absorb glucose, bring it into cells, and gradually return to equilibrium.

The problem arises when this regulation becomes less efficient: glucose remains elevated in the bloodstream for longer, tissues respond less well to insulin, and the pancreas must sustain higher insulin secretion to maintain normal blood glucose. This progressive loss of metabolic efficiency is driven by sedentary behaviour, muscle loss, poor sleep, chronic inflammation, and chronic stress.

Muscle: a major metabolic organ

Muscle is one of the primary tissues involved in glucose management after meals.

It represents a major site for glucose uptake and storage. The greater the muscle mass, the greater the body's capacity to use glucose efficiently and maintain good insulin sensitivity.

Conversely, when muscle mass decreases, the body has less metabolically active tissue available to capture and store glucose after meals. This is not the only factor at play, but it can progressively reduce metabolic flexibility. The system becomes less adaptive, and glucose regulation may require greater effort from the body.

Muscle mass tends to decrease progressively with age, and sedentary behaviour can accelerate this loss. In women, the menopausal transition also represents a period of metabolic vulnerability: hormonal changes can promote redistribution of body fat towards the abdominal region, alter recovery, and contribute, in some women, to less efficient glucose regulation.

This is also why some people feel that their metabolism "changes" after 40, sometimes without any major shift in diet.

Early signals are often dismissed

Metabolic decline is often described as silent. In reality, it can manifest through diffuse, non-specific signals, easily attributed to stress, age, or poor sleep:

• fatigue after meals;

• recurring sugar cravings;

• unstable energy levels;

• hunger returning quickly after eating;

• progressive abdominal fat accumulation;

• night wakings;

• brain fog;

• slower recovery;

• chronic low-grade inflammation.

Taken in isolation, these signals cannot confirm insulin resistance or a metabolic disorder. But when they become persistent, repeat, or are associated with suboptimal biological markers, they may indicate that the system is progressively losing flexibility and adaptive capacity.

Why certain biomarkers completely change the picture

In practice, most standard blood panels are limited to fasting glucose. Useful, but often insufficient to understand what is really happening. Because glucose can remain normal for a long time thanks to compensatory increases in insulin.

This is precisely why certain biomarkers are particularly informative:

• Fasting insulin: assesses whether the body is already producing large amounts of insulin to maintain normal blood glucose.

• HOMA-IR: an index calculated from fasting glucose and insulin, used to estimate insulin sensitivity.

• HbA1c: reflects average glucose exposure over approximately 2 to 3 months.

• Triglycerides: can increase when energy and lipid metabolism becomes less efficient, particularly in the context of energy excess or insulin resistance.

• HDL: provides an indication of the overall cardiometabolic profile.

• TG/HDL ratio: a useful indirect marker of insulin-resistant terrain and cardiometabolic risk.

• hsCRP: evaluates low-grade inflammation, frequently implicated in metabolic disorders.

• ALAT: rises in the presence of fatty liver (hepatic steatosis), closely linked to insulin resistance and metabolic dysregulation.

• Body composition (e.g. via DEXA scan): distinguishes fat mass, lean mass, and visceral fat, what weight alone cannot reveal.

No single biomarker tells the full story.

But interpreted together, in the context of sleep, stress, physical activity, diet, hormonal background, and symptoms, they often allow metabolic decline to be detected well before a diagnosed condition appears.

At Lucis, this is precisely the approach we advocate: not waiting for a system to become frankly pathological before beginning to understand the biological terrain as a whole.

Measure earlier. Understand more precisely. Act more intelligently.

What weight alone cannot show

Weight cannot distinguish between muscle mass, visceral fat, fat distribution, or bone density. Yet these parameters directly influence metabolic health, insulin sensitivity, recovery, and ageing.

This is why tools such as the DEXA scan can be particularly valuable: they provide a far more precise analysis of body composition than a standard scale.

We discuss this in the podcast

In this episode, Anaïs Gautron is joined by David D'Hont, expert in micronutrition, to explore insulin sensitivity, metabolic flexibility, the most relevant biomarkers, and the most effective nutritional and lifestyle strategies.

The information contained in this article is provided for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your lifestyle or medical monitoring.

References

1. Behboudi-Gandevani S, et al. Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis. Gynecological Endocrinology. 2016;32(5):343-353.

2. Berlanga-Acosta J, et al. Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review. Frontiers in Endocrinology. 2020;11.

3. Bird SR, Hawley JA. Update on the Effects of Physical Activity on Insulin Sensitivity in Humans. BMJ Open Sport & Exercise Medicine. 2017;2(1):e000143.

4. Bjornstad P, Eckel RH. Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review. Current Diabetes Reports. 2018;18(12):127.

5. Hu H, et al. Should insulin resistance (HOMA-IR) and visceral fat area be considered for improving the performance of diabetes risk prediction models. BMJ Open Diabetes Research & Care. 2024;12(1).

6. Kosmas CE, et al. Insulin resistance and cardiovascular disease. Journal of International Medical Research. 2023;51(3).

7. Mesarwi O, et al. Sleep Disorders and the Development of Insulin Resistance and Obesity. Endocrinology and Metabolism Clinics of North America. 2013;42(3):617-634.

8. Sung KC, et al. Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovascular Diabetology. 2011;10(1):108.

9. Wolfe RR. The underappreciated role of muscle in health and disease. American Journal of Clinical Nutrition. 2006;84(3):475-482.

10. Zhao X, An X, Yang C, et al. The crucial role and mechanism of insulin resistance in metabolic disease. Frontiers in Endocrinology. 2023;14:1149239.